Atara biotherapeutics announces closing of expanded global tab-cel® partnership with pierre fabre laboratories

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with pierre fabre laboratories for tabelecleucel (tab-cel® or ebvallotm). building on the earlier partnership announced in october 2021 to commercialize tab-ce.
ATRA Ratings Summary
ATRA Quant Ranking